Quarterly ResultMay 15, 2026, 04:49 PM
Citius Pharma Q2 Net Loss $(21.2)M; LYMPHIR Revenue $1.7M; Secures $41.5M Financing
AI Summary
Citius Pharmaceuticals reported its fiscal second quarter 2026 financial results, with net product revenues of $1.7 million from the ongoing launch of LYMPHIR. The company recorded a net loss of $21.2 million, or $(0.95) per share, primarily due to a $19.7 million one-time CMO contract cancellation charge. Citius Oncology, its majority-owned subsidiary, demonstrated strong commercial progress for LYMPHIR, securing near 100% payer coverage for commercial lives. Subsequent to quarter-end, Citius Pharma raised $5 million, and Citius Oncology secured up to $36.5 million in financing, extending the operational runway through November 2026.
Key Highlights
- Citius Pharma reported Q2 2026 net product revenues of $1.7 million from LYMPHIR launch.
- Net product revenues for the first half of fiscal 2026 were $5.6 million.
- Q2 2026 net loss applicable to common stockholders was $(21.2) million, or $(0.95) per share.
- General and administrative expenses for Q2 2026 were $26.4 million, including a $19.7 million CMO contract cancellation charge.
- Citius Pharma raised $5 million in a registered direct offering in April 2026.
- Citius Oncology secured up to $36.5 million in debt and equity financing subsequent to quarter end.
- LYMPHIR achieved near 100% payer coverage for commercial lives and 83% of target accounts on formulary or in review.
- Cash and cash equivalents were $4.6 million as of March 31, 2026.
Price Impact
More from CTXR